Xeljanz (Tofacitinib)

Save over 65% with brand name Xeljanz from Pfizer and over 94% with the generic version.

Click here for information on Cipla generics (Immediate availability)

Xeljanz is a medicine used to treat inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.  Xeljanz is used alone or in combination with methotrexate.  Xeljanz is clinically shown to reduce swelling and pain in joints and improve mobility required for regular daily activities.

Information about Xeljanz (Tofacitinib)

Xeljanz contains tofacitinib, which is a Janus kinase (JAK) inhibitor that works by targeting specific enzymes involved in the inflammatory process. By inhibiting these enzymes, Xeljanz helps to reduce inflammation and manage symptoms of autoimmune diseases. It is an oral medication that has been approved for several autoimmune conditions, helping to reduce pain, swelling, and other symptoms associated with chronic inflammation.

Product Highlights

• Xeljanz is used to treat moderate to severe rheumatoid arthritis in adults who have not responded adequately to methotrexate or other disease-modifying antirheumatic drugs (DMARDs).
• It is indicated for adults with active psoriatic arthritis to improve symptoms and prevent joint damage.
• Xeljanz is used for the treatment of moderate to severe ulcerative colitis in adults who have not responded to other treatments.
• Xeljanz is sometimes used in clinical settings for other conditions under the guidance of a healthcare provider.

Key Ingredient

• Tofacitinib

Key Benefits

• Xeljanz helps reduce inflammation, alleviating symptoms such as pain, swelling, and stiffness in conditions like rheumatoid arthritis.
• In rheumatoid arthritis and psoriatic arthritis, Xeljanz helps reduce joint damage and improve overall mobility and function.
• Xeljanz offers a convenient oral alternative to other treatments that may require injections or intravenous administration.
• For patients who do not respond to conventional therapies like methotrexate, Xeljanz can provide an effective treatment option for managing symptoms and improving quality of life.

Direction of Use

• The typical starting dose for Xeljanz is 5 mg twice daily, though this may vary based on the condition being treated and the individual patient's response. In some cases, your doctor may adjust the dose.
• Xeljanz should be taken orally, with or without food, as directed by your healthcare provider. Always follow your prescribed dosage and do not alter the dose without consulting your doctor.
• If you miss a dose, take it as soon as you remember, unless it's almost time for your next dose. Do not take two doses at once to make up for a missed dose.
• Take Xeljanz at the same time each day to help you remember and ensure consistent therapeutic effects.

Safety Concerns

• Xeljanz may increase the risk of serious infections, including tuberculosis, bacterial, fungal, or viral infections. Patients should be screened for tuberculosis and other infections before starting treatment.
• Liver function should be monitored, as Xeljanz can cause liver problems in some individuals. Your doctor may perform blood tests to check liver function regularly.
• Xeljanz has been associated with an increased risk of blood clots, including deep vein thrombosis (DVT) and pulmonary embolism (PE), especially in those using higher doses or with certain pre-existing conditions.
• Long-term use of Xeljanz may increase the risk of certain types of cancer, including lymphoma. Patients should be monitored for any signs of cancer.
• Xeljanz may cause changes in lipid (cholesterol) levels, so regular monitoring of cholesterol levels is recommended during treatment.
• There is some evidence that Xeljanz may increase the risk of bone fractures, particularly in patients with pre-existing bone conditions.

Avoid Xeljanz (Tofacitinib) If

• You should avoid Xeljanz if you have any active infection, as the medication may suppress your immune system and make it harder to fight infections.
• If you have a history of blood clots, especially deep vein thrombosis or pulmonary embolism, you should not use Xeljanz or use it with caution, as it may increase the risk.
• Xeljanz is contraindicated in individuals with severe liver impairment.
• Xeljanz should be avoided during pregnancy unless the potential benefits outweigh the risks. It is not recommended for breastfeeding due to potential risks to the infant.
• If you have had a severe allergic reaction to tofacitinib or any of the ingredients in Xeljanz, you should not use this medication.